A complementary phase 1 follow-up clinical trial will also be conducted in the United States to investigate its therapeutic potential and side effects in T1D patients who use insulin and have no other diabetes-related health complications (Clinicaltrials.gov identifier: NCT04590872). This evidence concerns the gene INS and type 1 diabetes mellitus.